摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(3S,10R,13S,17R)-17-benzyl-10,13-dimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone

中文名称
——
中文别名
——
英文名称
1-[(3S,10R,13S,17R)-17-benzyl-10,13-dimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
英文别名
——
1-[(3S,10R,13S,17R)-17-benzyl-10,13-dimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone化学式
CAS
——
化学式
C35H44O2
mdl
——
分子量
496.7
InChiKey
GSINAFUVIQKUCO-FYYXCXMQSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    7.9
  • 重原子数:
    37
  • 可旋转键数:
    6
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • 3-(4'-SUBSTITUTED)-BENZYL-ETHER DERIVATIVES OF PREGNENOLONE
    申请人:INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    公开号:US20150284423A1
    公开(公告)日:2015-10-08
    The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO 2 , amino, COOH, COOCH 3 , OH, N 3 , or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally substituted.
    本发明涉及化合物I式或其药学上可接受的盐:其中R1为C1-8烷基,C1-8烷氧基,CN,NO2,氨基,COOH,COOCH3,OH,N3或卤素,R2为H,OH,C1-8烷基,C1-8烷氧基,C2-C6烯基,卤素,Bn-O—,Bn-选择性取代,或Ph-选择性取代。
  • Antagonists of CB1 receptor
    申请人:INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    公开号:US10040816B2
    公开(公告)日:2018-08-07
    The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    本发明涉及一种 CB1 受体拮抗剂,用于治疗选自以下组别的病理状况或紊乱:膀胱和胃肠道疾病;炎症性疾病;心血管疾病;肾病;青光眼;痉挛;癌症;骨质疏松症;代谢紊乱;肥胖;成瘾、依赖、滥用和复发相关紊乱;精神和神经紊乱;神经退行性疾病;自身免疫性肝炎;骨质疏松症;代谢紊乱;肥胖;成瘾、依赖、滥用和复发相关疾病;精神和神经系统疾病;神经退行性疾病;自身免疫性肝炎和脑炎;疼痛;生殖系统疾病以及皮肤炎症和纤维化疾病。
  • 3-(4′-substituted)-benzyl-ether derivatives of pregnenolone
    申请人:INSERM (Institut National de la Sante et de la Recherche Medicale)
    公开号:US10259839B2
    公开(公告)日:2019-04-16
    The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally substituted.
    本发明涉及式(I)化合物或其药学上可接受的盐:其中 R1 是 C1-8 烷基、C1-8 烷氧基、CN、NO2、氨基、COOH、COOCH3、OH、N3 或卤素,R2 是 H、OH、C1-8 烷基、C1-8 烷氧基、C2-C6 烯基、卤素、Bn-O-、任选取代的 Bn-或任选取代的 Ph-。
  • Antagonists of CB1 Receptor
    申请人:INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    公开号:US20160145294A1
    公开(公告)日:2016-05-26
    The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
  • ANTAGONISTS OF CB1 RECEPTOR
    申请人:Piazza Pier Vincenzo
    公开号:US20190071465A1
    公开(公告)日:2019-03-07
    The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
查看更多